Prostate Cancer International is
for 2011 by Great NonProfits
According to a media release this morning, the global pharmaceutical company Astellas has licensed rights to commercialize Medivation’s investigational prostate cancer drug MDV3100.
Filed under: Drugs in development | Tagged: MDV3100 | Leave a Comment »
According to a media release from Medivation, Inc. earlier today, the company has treated the first patient in a Phase III clinical trial of the novel androgen receptor antagonist MDV3100 in advanced prostate cancer.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, MDV3100 | 2 Comments »
On Saturday there were two major prostate cancer sessions and additional poster sessions that included prostate cancer-related material at the annual meeting of the American Society for Clinical Oncology.
Filed under: Drugs in development, Management, Treatment | Tagged: MDV3100, OGX-011, PROSTVAC-VF, vaccines | Leave a Comment »
There are several stories on the Web today about a forthcoming article in Science giving data about a phase I/II trial of MDV3100.
Filed under: Drugs in development, Management, Treatment | Tagged: MDV3100 | Leave a Comment »
There are six new reports in today’s news, of which the most immediately important would seem to be: How men manage their “fear” while on active surveillance “Cancer anxiety” and early use of hormonal therapy Approval for a Phase III clinical trial of MDV3100
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active suirveillance, cancer anxiety, denosumab, forkhead transcription factors, FOX factors, hormone therapy, MDV3100, testosterone | Leave a Comment »
Looking through my assorted notes from the meeting this morning after getting home late last night, there are four other poster presentations that are worth commenting on very specifically, and then a general comment that I would add.
Filed under: Management, Treatment | Tagged: abiraterone, active surveillance, anxiety, cost, depression, MDV3100, radical prostatectomy | Leave a Comment »
In the prostate cancer research news today, there are two new developments and a report of another failure. So first the bad news …
Filed under: Drugs in development, Management, Treatment | Tagged: 17-AAG, MDV3100, UroCool | Leave a Comment »
Medscape has just published an extensive update on the ongoing Phase I/II clinical trial of MDV3100 an investigational androgen-receptor antagonist for use in the treatment of advanced prostate cancer.
Filed under: Drugs in development, Treatment | Tagged: MDV3100 | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site